Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth ...

Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1370 in its research report dated April 30, 2026.

Laurus Labs Ltd. reached a new record high in May 2026, with experts suggesting the rally will continue. The stock has shown ...

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, ...

Laurus Labs Ltd. broke out from a five-month consolidation on monthly charts, reaching fresh record highs in May. Experts ...

LAURUSLABS surged on June 1. The stock opened at Rs 334.65, up over 2 per cent from its Wednesday's close of Rs 330.7 on the ...

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Gland Pharma jumped 15.85 per cent to Rs 2,164.40, while Sun Pharma climbed 1 per cent to Rs 1,896.90. Laurus Labs moved up 0 ...

In a report released today, from BOB Capital Markets maintained a Hold rating on Laurus Labs Ltd., with a price target of INR1,160.00.

In a report released today, Alok Dalal from Jefferies maintained a Hold rating on Laurus Labs Ltd., with a price target of INR1,100.00. Dalal covers the Healthcare sector, focusing on stocks such as ...

We analyzed narration versus actual outcomes and financial performance across CDMO peers, highlighting an uneven recovery, with some companies facing guidance resets due to program delays, destocking, ...